OncoTricks

Colorectal first line; penile cancer with nodes, Nov 19, 2026

Metastatic colorectal cancer, first line

Must Be Really Sure before cycle 1

Mismatch repairBRAFRASSide
splenic flexure RIGHTcecum, ascending, transverse LEFTdescending, sigmoid, rectum EGFR antibody plus chemotherapyhelps here only, if RAS and BRAFare wild type

Algorithm

Metastatic colorectal adenocarcinomaDay 1 orders: mismatch repair, BRAF, RAS, DPYD
M. Mismatch repair deficient?Cannot fix DNA copying errors. Same as MSI-high (microsatellite instability).
Yes
Immunotherapy alonePembrolizumabends here
No
B. BRAF V600E?The one BRAF mutation with a matched drug.
Yes
Encorafenib + cetuximab + FOLFOX
No
R and S. RAS wild type AND primary on the left?RAS = KRAS and NRAS; wild type = no mutation. RAS mutated = an EGFR antibody added to chemotherapy does not work.
Yes to both
Doublet + EGFR antibodyHighest response: good when liver surgery is the goal
No: RAS mutated or right side
Chemotherapy + bevacizumabDoublet, or triplet if fit. No biomarker-matched drug to add.
Every branch with fluorouracil or capecitabine: DPYD result before cycle 1
No variantFull dose
One variant copyStart at half dose. Raise if the first two cycles are tolerated.
Two variant copiesAvoid both drugs. Discuss with pharmacy.

Doublet = FOLFOX or FOLFIRI · Triplet = FOLFOXIRI · EGFR (epidermal growth factor receptor) antibody = cetuximab, panitumumab

Median months, new regimen in blue

KEYNOTE-177 · mismatch repair deficient · months without progression

Pembrolizumab16.5
Chemotherapy8.2

BREAKWATER · BRAF V600E · months alive

With encorafenib30.3
Chemotherapy15.1

PARADIGM · RAS wild type, left side · months alive

Panitumumab37.9
Bevacizumab34.3
Sources

Retrieved from PubMed and the FDA, checked Nov 20, 2026.

  1. André T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer (KEYNOTE-177). N Engl J Med 2020. PubMed 33264544 · doi:10.1056/NEJMoa2017699
  2. Elez E, et al. Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer (BREAKWATER). N Engl J Med 2025. PubMed 40444708 · doi:10.1056/NEJMoa2501912
  3. Watanabe J, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer (PARADIGM). JAMA 2023. PubMed 37071094 · doi:10.1001/jama.2023.4428
  4. Cremolini C, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab (TRIBE2). Lancet Oncol 2020. PubMed 32164906 · doi:10.1016/S1470-2045(19)30862-9
  5. Amstutz U, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 2018, with the November 2018 online update. PubMed 29152729 · doi:10.1002/cpt.911
  6. Henricks LM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018. Half dose was adequate for the two most severe variants; a 25% reduction was not enough for the two milder ones. PubMed 30348537 · doi:10.1016/S1470-2045(18)30686-7
  7. Ison G, et al. FDA approval: uridine triacetate for the treatment of patients following fluorouracil or capecitabine overdose or exhibiting early-onset severe toxicities. Clin Cancer Res 2016. PubMed 27401247 · doi:10.1158/1078-0432.CCR-16-0638
  8. FDA. Safety labeling update for capecitabine and fluorouracil: risks associated with dihydropyrimidine dehydrogenase deficiency. Communication of Feb 5, 2026. fda.gov

Penile cancer, positive nodes

Clinical node category (cN): groin exam plus imaging

cN0
Nothing palpableStage the groin or watch
cN1
One mobile node, one sideDissection
cN2
Several mobile nodes, or both sidesOne side, under 4 cm: dissectionBulky or both sides: TIP first
cN3
Fixed mass, or pelvic nodesTIP first

p16 = the stain that stands in for HPV (human papillomavirus). Positive = better prognosis.

Algorithm

Penile squamous cell carcinomaFeel both groins, image groins and pelvis: palpable or suspicious node?
No: cN0
Primary invades deeper or is high grade (pT1b or higher): stage the groinSentinel node biopsy. Otherwise surveillance.
Yes
Needle biopsy firstTissue proof before any treatment.
Positive
cN1, or cN2 one side, mobile, under 4 cm
Inguinal lymph node dissection
Then, by pathology3 or more positive nodes on one side, or spread outside the node: pelvic dissection, adjuvant radiation. Tumor board.
cN3, or cN2 bulky (4 cm or more) or both sides
Chemotherapy first: TIP x 4Paclitaxel, ifosfamide, cisplatin
On a booster (ritonavir, cobicistat)?Before cycle 1, ask the HIV team and pharmacy about an unboosted regimen. Switch, never stop.
Restage
Response or stable
Consolidative dissectionInguinal and pelvic
Progression
No dissectionChemoradiation, next line or trial

EAU-ASCO 2023 rates chemotherapy first as a weak recommendation; randomized answer (InPACT) pending.

TIP before surgery: 30 men

15 responded22 reached surgery3 had no tumor left at surgery9 alive without recurrence at a median of 34 months

Phase II, single arm (Pagliaro, J Clin Oncol 2010). cN2 or cN3.

TIP: 4 cycles, every 3 to 4 weeks

T
Paclitaxel 175 mg/m², day 1. Premedicate. Neuropathy stacks with cisplatin.
I
Ifosfamide 1,200 mg/m², days 1 to 3. Mesna (the bladder protector) every dose. Low albumin = more encephalopathy. Confused or sleepy: stop the infusion; methylene blue is used to treat.
P
Cisplatin 25 mg/m², days 1 to 3. Creatinine, magnesium, potassium, hearing.

All three hit the marrow: consider growth factor from cycle 1.

Boosters and TIP

Booster = ritonavir or cobicistatBlocks CYP3A4 (a liver enzyme), so chemotherapy cleared by CYP3A4 changes too. Unboosted option: for example dolutegravir based.
PaclitaxelCleared by CYP2C8 and CYP3A4Can raise the level: watch neuropathy and counts
IfosfamideSwitched on by CYP3A4Less active drug likely; neurotoxic pathway not reduced

Fixed, Bulky, Bilateral or Pelvic: TIP before the knife.

Sources

Retrieved from PubMed, ClinicalTrials.gov and the EAU-ASCO recommendation table, checked Nov 20, 2026.

  1. Pagliaro LC, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010. PubMed 20625118 · doi:10.1200/JCO.2010.29.5477
  2. Brouwer OR, et al. European Association of Urology-American Society of Clinical Oncology collaborative guideline on penile cancer: 2023 update. Eur Urol 2023. PubMed 36906413 · doi:10.1016/j.eururo.2023.02.027
  3. NCCN Guidelines: Penile Cancer (4 cm node size cutoff), current version.
  4. Mustasam A, et al. The prognostic role of HPV or p16INK4a status in penile squamous cell carcinoma: a meta-analysis. J Natl Compr Canc Netw 2025. PubMed 39752880 · doi:10.6004/jnccn.2024.7078
  5. InPACT, NCT02305654: active, not recruiting, no results posted. ClinicalTrials.gov
  6. David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 2005. PubMed 15923801 · doi:10.1097/01.coc.0000158439.02724.5a
  7. Richards A, et al. Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity (retrospective; prevention did not lower the rate). J Oncol Pharm Pract 2011. PubMed 20861178 · doi:10.1177/1078155210385159
  8. Kerbusch T, et al. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin (small study; the booster effect is extrapolated from ketoconazole). Clin Pharmacol Ther 2001. PubMed 11503007 · doi:10.1067/mcp.2001.117283
  9. Strope JD, et al. Drug-drug interactions in patients with HIV and cancer in Sub-Saharan Africa. AIDS Rev 2020. PubMed 33105469 · doi:10.24875/AIDSRev.20000005
  10. Branch C, et al. Drug-drug interactions in HIV-infected patients receiving chemotherapy. Expert Opin Drug Metab Toxicol 2025. PubMed 39305240 · doi:10.1080/17425255.2024.2408004